1. Home
  2. |Insights
  3. |DoD Startup DIUx Expands Footprint

DoD Startup DIUx Expands Footprint

Client Alert | less than 1 min read | 09.19.16

On September 14, the Defense Innovation Unit Experimental, or DIUx, which already has offices in Silicon Valley and Boston, announced its expansion to Austin, Texas. DIUx, which has 22 projects in the pipeline totaling $65 million of forthcoming investment, is focused on bringing high-tech firms into the government contracting marketplace to augment DoD’s capabilities in areas such as autonomy, artificial intelligence, and machine learning and presents a unique contracting platform for such firms, though, as with other federal contracting opportunities, doing business with DIUx will subject tech firms to terms and conditions that differ in material ways from purely commercial agreements.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights